Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients
- 1 June 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2803-2812
- https://doi.org/10.1128/aac.01718-10
Abstract
Influenza virus infections are known to persist longer in patients with underlying diseases, including respiratory tract diseases, and tend to become complicated by secondary influenza-associated infections, such as pneumonia. To assess the efficacy and safety of the novel anti-influenza virus drug peramivir in high-risk patients, we conducted a clinical trial of patients with diabetes or chronic respiratory tract diseases and patients being treated with drugs that suppress immune function. In this multicenter, uncontrolled, randomized, double-blind study, peramivir was intravenously administered at 300 or 600 mg/day for 1 to 5 days, as needed. Efficacy was investigated in 37 patients (300 mg,n= 18 patients; 600 mg,n= 19 patients). The median durations of influenza illness were 68.6 h (90% confidence interval, 41.5 to 113.4 h) overall, 114.4 h (90% confidence interval, 40.2 to 235.3 h) in the 300-mg group, and 42.3 h (90% confidence interval, 30.0 to 82.7 h) in the 600-mg group. The hazard ratio for the 600-mg group compared to the 300-mg group was 0.497 (90% confidence interval, 0.251 to 0.984), and the duration of influenza illness was significantly shorter in the 600-mg group than in the 300-mg group. Among the 42 patients in the safety analysis set, adverse events occurred in 73.8% and adverse drug reactions in 33.3%. No adverse events were particularly problematic clinically, and all patients recovered quickly from all events. The measured blood drug concentrations showed no tendency toward accumulation. Drug accumulation with repeated doses was thus considered to be of little concern. Intravenous peramivir appears to offer a potentially useful treatment for high-risk patients in the future.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2010
- Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised HostsClinical Infectious Diseases, 2010
- Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South AfricaAntiviral Research, 2009
- Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?Clinical Infectious Diseases, 2009
- Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 InfluenzaPLOS ONE, 2008
- Anti-influenza virus activity of peramivir in mice with single intramuscular injectionAntiviral Research, 2005
- A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese populationCurrent Medical Research and Opinion, 2005
- Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant VariantsAntimicrobial Agents and Chemotherapy, 2001
- Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and ZanamivirAntimicrobial Agents and Chemotherapy, 2001
- Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European StudyJournal of Infection, 2000